

22096



CERTIFICATE OF EXPRESS MAIL
FIRST CLASS MAILING
I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail, or as
Express Mail if the number of the Express
Mail mailing label is provided below, in an
envelope addressed to: Commissioner of
Patents and Trademarks, Washington, DC
20231, on MAR 21 2002
(Date of Deposit)

IN THE U.S. PATENT AND TRADEMARK OFFICE

Express Mail Label Number
EV018431575

Inventor Zoltan GREFF et al
Patent App. 10/030,436 (US Nat'l phase of PCT/HU00/00074)
Filed 4 January 2002
For 2,3-BENZODIAZEPINE DERIVATIVES
Hon. Commissioner of Patents
Washington, DC 20231

RECORD OF TRANSMITTAL--PCT APPLICATION

- ☒ PCT Transmittal
- ☐ PCT Application
- ☐ Translation
- ☐ Sheets of Drawing (0)
- ☒ PCT Declaration
- ☐ PCT Documents
- ☐ International Search Report
- ☐ Preliminary Amendment
- ☒ Assignment (with PTO-1595 and sep. PTO-2038)
- ☒ PTO-2038 for Official Fees

☒ Late filing \$130.00

Total \$130.00

Please charge any fees not covered by an enclosed PTO-2038 to
account 18-2025 of the undersigned.

21 March 2002

5676 Riverdale Ave. Box 900
Bronx, NY 10471-0900
Tel: (718) 884-6600
Fax: (718) 601-1099
Customer No. 535
rg

Respectfully submitted,
The Firm of Karl F. Ross P.C.


Herbert Dubno, Reg. 19,752

22096

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 USC 371

US. Application No. (if known)

10/030436

INTERNATIONAL APP. NO.

PCT/HU00/00074

INTERNATIONAL FILING DATE

4 July 2000

PRIORITY DATE CLAIMED

7 July 1999

TITLE OF INVENTION

2,3-BENZODIAZEPINE DERIVATIVES

APPLICANT(S) FOR DO/EO/US

Zoltan GREFF et al

Applicant herewith submits to the United States Designated/Elected Office (DO/EU/US) the following .

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☐ This is an express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 317(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 USC 371(c)(2)).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau.
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Patent Office.
6. ☐ A translation of the International application into English.
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau.
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3).
9. ☒ An oath or declaration of the inventor(s) (35 USC 371(c)(4).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11. to 16. below concern documents or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An Assignment for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items of information.

